Mon, Jun 24, 9:22 PM (119 days ago)
Beyond Air, Inc.'s Form 10-K for the fiscal year ended March 31, 2024, highlights key aspects of its financial performance, strategic initiatives, and risk factors. The company reported an accumulated deficit of approximately $239.7 million and net cash used in operating activities of $56.0 million for the year. Beyond Air's primary product, LungFit® PH, received FDA approval in June 2022 and is marketed for treating persistent pulmonary hypertension of the newborn (PPHN). The company is also developing other indications and products, including LungFit® PRO and LungFit® GO, targeting viral lung infections and nontuberculous mycobacteria (NTM) lung infections, respectively. Future capital needs are anticipated, with a $40 million loan agreement established to support growth. Key risks include competition, market acceptance, regulatory hurdles, and cybersecurity threats. The company aims to expand its market presence and achieve profitability through strategic product development and commercialization efforts.